Group managing director Leonard Ariff Abdul Shatar said the company has maintained its position as the leading pharmaceutical company in Malaysia in terms of sales volume and number two in terms of value, which was aided by strong performance of its CHC business.
KUALA LUMPUR: Duopharma Biotech Bhd
plans to implement a four-pronged strategy to expand its consumer healthcare (CHC) product portfolios, diversify into high-value biologicals and niche products, upgrade manufacturing facilities and enhance its Asean presence.
Group managing director Leonard Ariff Abdul Shatar said the company has maintained its position as the leading pharmaceutical company in Malaysia in terms of sales volume and number two in terms of value, which was aided by strong performance of its CHC business.
Get 30% off with our ads free Premium Plan!
